Breast Cancer — Microlearning Activity 1 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates
Oncology Today with Dr Neil Love
00:00
COMPASS HER2-RD and Tucatinib Addition
Dr Sharma describes the Alliance COMPASS HER2-RD trial comparing TDM1 with TDM1 plus tucatinib, now fully accrued.
Play episode from 05:36
Transcript
